We are live on
!
Find out more
VCM
Versant Capital Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
34.21%
This Fund
S&P 500
This Quarter
Est. Return
+13.52%
1 Year Est. Return
+34.21%
3 Year Est. Return
+82.39%
5 Year Est. Return
+89.4%
10 Year Est. Return
+245.39%
AUM
$1.12B
AUM Growth
+$101M
(+10%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
1.71%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
2,873
New
96
Increased
1,181
Reduced
859
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DXUV
Dimensional US Vector Equity ETF
DXUV
|
+$8.37M |
| 2 |
Dimensional Emerging Markets Core Equity 2 ETF
DFEM
|
+$7.66M |
| 3 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$6.75M |
| 4 |
DXIV
Dimensional International Vector Equity ETF
DXIV
|
+$4.35M |
| 5 |
Dimensional Emerging Markets Value ETF
DFEV
|
+$2.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 3-7 Year Treasury Bond ETF
IEI
|
+$2.11M |
| 2 |
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
|
+$2.02M |
| 3 |
Vanguard Total Stock Market ETF
VTI
|
+$1.88M |
| 4 |
CoreCivic
CXW
|
+$1.84M |
| 5 |
Apple
AAPL
|
+$1.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.06% |
| 2 | Financials | 7.05% |
| 3 | Industrials | 6.04% |
| 4 | Consumer Discretionary | 4.74% |
| 5 | Healthcare | 4.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
JBIO
1926
Jade Biosciences
JBIO
$1.22B
| $20.1K | ﹤0.01% |
905
| – | – |
|
1927
Red Rock Resorts
RRR
$3.74B
| $20K | ﹤0.01% |
308
-95
| -24% | -$5.41K |
|
1928
BioCryst Pharmaceuticals
BCRX
$2.37B
| $20K | ﹤0.01% |
2,003
+1,521
| +316% | +$13.8K |
|
1929
Constellation Brands
STZ
$22.2B
| $20K | ﹤0.01% |
144
-57
| -28% | -$8.47K |
|
1930
Prothena Corp
PRTA
$458M
| $20K | ﹤0.01% |
2,044
-148
| -7% | -$1.46K |
|
|
GOLD
1931
Gold.com Inc
GOLD
$1.14B
| $19.9K | ﹤0.01% |
479
| – | – |
|
1932
Genie Energy
GNE
$378M
| $19.9K | ﹤0.01% |
1,379
-652
| -32% | -$9.12K |
|
1933
Amerant Bancorp
AMTB
$1.12B
| $19.7K | ﹤0.01% |
773
| – | – |
|
1934
Ingevity
NGVT
$2.55B
| $19.7K | ﹤0.01% |
264
| – | – |
|
1935
Stoneridge
SRI
$209M
| $19.7K | ﹤0.01% |
2,693
-38
| -1% | -$261 |
|
1936
Willdan Group
WLDN
$1.1B
| $19.7K | ﹤0.01% |
249
+72
| +41% | +$6.13K |
|
1937
Mattel
MAT
$4.17B
| $19.7K | ﹤0.01% |
1,417
-6,023
| -81% | -$88.1K |
|
1938
TeraWulf
WULF
$9.15B
| $19.6K | ﹤0.01% |
795
+569
| +252% | +$13.1K |
|
1939
Atea Pharmaceuticals
AVIR
$379M
| $19.6K | ﹤0.01% |
+4,220
| New | +$21K |
|
|
CON
1940
Concentra Group Holdings
CON
$4.04B
| $19.6K | ﹤0.01% |
659
| – | – |
|
1941
FRP Holdings
FRPH
$449M
| $19.4K | ﹤0.01% |
778
-1,734
| -69% | -$39.3K |
|
1942
Live Nation Entertainment
LYV
$41.2B
| $19.4K | ﹤0.01% |
106
-165
| -61% | -$27.1K |
|
1943
State Street SPDR S&P 400 Mid Cap Growth ETF
MDYG
$2.82B
| $19.4K | ﹤0.01% |
173
| – | – |
|
1944
Crown Castle
CCI
$32.7B
| $19.3K | ﹤0.01% |
255
+10
| +4% | +$878 |
|
1945
Bank First Corp
BFC
$1.67B
| $19.3K | ﹤0.01% |
+130
| New | +$18.6K |
|
1946
Hecla Mining
HL
$10.2B
| $19.2K | ﹤0.01% |
1,247
-186
| -13% | -$3.27K |
|
1947
Preferred Bank
PFBC
$1.22B
| $19.2K | ﹤0.01% |
181
| – | – |
|
1948
Carlisle Companies
CSL
$13.6B
| $19.2K | ﹤0.01% |
53
-18
| -25% | -$6.3K |
|
1949
PureCycle Technologies
PCT
$1.17B
| $19.2K | ﹤0.01% |
2,370
| – | – |
|
1950
Invesco FTSE RAFI Developed Markets ex-US Small-Mid ETF
PDN
$349M
| $19.2K | ﹤0.01% |
427
| – | – |
|
Similar funds
FLAM
AIM
MTCM
CNC
NOSC
RIM
ACG
C
Versant Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Versant Capital Management held 2,873 positions worth $1.12B, up 10% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Versant Capital Management's Q2 2026 filing shows 96 new, 1,181 increased, 859 reduced and 128 closed positions. Its largest new stake was AstraZeneca: 7,263 shares worth $1.36M. The largest sale was iShares 3-7 Year Treasury Bond ETF, an estimated $2.11M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Industrials.
- Versant Capital Management's largest Q2 2026 buy was AstraZeneca: 7,263 shares worth $1.36M.
- Versant Capital Management added most to Dimensional US Vector Equity ETF in Q2 2026, an estimated $8.37M increase.
- Versant Capital Management's biggest Q2 2026 reduction was iShares 3-7 Year Treasury Bond ETF, cutting an estimated $2.11M.
- Versant Capital Management fully exited iShares 5-10 Year Investment Grade Corporate Bond ETF in Q2 2026, selling an estimated $2.02M.
- Versant Capital Management's ten largest holdings make up 32% of its $1.12B portfolio in Q2 2026.
- Versant Capital Management opened 96 new positions and closed 128 in Q2 2026.
- Versant Capital Management's portfolio value rose 10% quarter-over-quarter to $1.12B.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.